Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341

REFERENCES

• Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9(6):415–428.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769–784.
   PubMed Web of Science ®Google Scholar
• Marchion D, Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007;7(4):583–598.
   PubMed Web of Science ®Google Scholar
• Carey N, La Thangue NB. Histone deacetylase inhibitors: gathering pace. Curr Opin Pharmacol 2006, 6(4):369–375.
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphom. Expert Opin Investig Drugs 2007;16:1111–1120.
   PubMed Web of Science ®Google Scholar
• Zhu K, Qu D, Sakamoto T, Fukasawa I, Hayashi M, Inaba N. Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors. Arch Gynecol Obstet 2008;277(1):15–19.
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4(5):349–360.
   PubMed Web of Science ®Google Scholar
• Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003;4: 192–201.
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003;29(Suppl. 1):3–9.
   PubMed Web of Science ®Google Scholar
• Ling YH, Liebes L, Jiang J.D, Holland J.F, Elliott P.J, Adams J, Muggia F.M, Perez-Soler R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9(3):1145–1154.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101(6):2377–2380.
   PubMed Web of Science ®Google Scholar
• Russo A, Fratto ME, Bazan V, Schiro V, Agnese V, Cicero G, Vincenzi B, Tonini G, Santini D. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. Expert Opin Ther Targets 2007;11(12):1571–1586.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10(11):3839–3852.
   PubMed Web of Science ®Google Scholar
• Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR. Combined proteasome and histone deacetylase inhibitor in non-small cell lung cancer. J Thorac Cardiovasc Surg 2004;127:1078–1986.
   PubMed Web of Science ®Google Scholar
• Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007;6(1):37–50.
   PubMed Web of Science ®Google Scholar
• Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 2008;271(2): 260–271.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009;280(2): 192–200.
   PubMed Web of Science ®Google Scholar
• Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009;280(2):125–133.
   PubMed Web of Science ®Google Scholar
• Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih Ie M, Roden RB. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006;66(7):3754–3763.
   PubMed Web of Science ®Google Scholar
• Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2006;6:3719–3728.
   Google Scholar
• Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici P, Cognetti F, Humphreys R, Peschle C, Testa U. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007;12(4):635–655.
   PubMed Web of Science ®Google Scholar
• Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2000;10:3839–3852.
   Google Scholar
• Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, Cleveland JL, Giles FJ, McConkey DJ. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008;112(7):2917–2926.
   PubMed Web of Science ®Google Scholar
• Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA, Waterhouse NJ, Trapani JA, Johnstone RW. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63(15):4460–4471.
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009;9:400–414.
   PubMed Web of Science ®Google Scholar
• Luo Y, Hurwitz J, Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995;375(6527):159–161.
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002;1(11):937–941.
   PubMed Web of Science ®Google Scholar
• Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett 2002;179(1):1–14.
   PubMed Web of Science ®Google Scholar
• Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43–M56.
   PubMed Web of Science ®Google Scholar
• Gartel AL. The conflicting roles of the cdk inhibitor p21CIP1/WAF1 in apoptosis. Leuk Res 2005;29:1237–1238.
   PubMed Web of Science ®Google Scholar